European and Israeli researchers are working together on the development of a clinical management system for the use of drugs and drug combinations given to HIV patients, as part of an EU-funded project.

The number of applications for marketing authorisations submitted to the European Medicines Agency (EMEA) remains strong according to the half-year report presented to the Agency's Management Board by Thomas Lönngren, EMEA Executive Director, at its 4 October 2007 meeting.

Transinsight, provider of knowledge-based software solutions, has released a new online version of the well-known life-science search engine www.GoPubMed.org. This, the first semantic search engine, reduces search time by up to 90%. By sorting search results it enables scientists to answer biomedical questions in completely new way.

European consumers have been a long-neglected piece of the strategic puzzle for most marketers at health and pharmaceutical companies. Yet signs increasingly point to the degree to which European consumers are, in fact, researching health information and treatment options, and ultimately taking action as a result of those information searches.

Collexis (OTCBB: CLXS), a leading developer of high-definition search and discovery software, and their German partner, SyynX Solutions, announced they will preview a new life sciences social networking site to representatives from global book publishing and multimedia companies at the Frankfurt Book Fair in Frankfurt, Germany.

Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, announced the launch of Enterprise Alert Manager, an integrated RSS management and collaboration solution designed to simplify information distribution across an organization by allowing for easy deployment while reducing email load and network strain.

Finalising a review of the liver safety of systemic formulations of medicines containing nimesulide, the European Medicines Agency (EMEA) has concluded that the benefits of these medicines outweigh their risks, but that there is a need to limit the duration of use and to restrict their use to ensure that the risk of patients developing liver problems is kept to a minimum.